Cargando…

Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis

BACKGROUND: The soluble receptor for advanced glycation end-products (sRAGE) has been suggested that it acts as a decoy for capturing advanced glycation end-products (AGEs) and inhibits the activation of the oxidative stress and apoptotic pathways. Lung AGEs/sRAGE is increased in idiopathic pulmonar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machahua, Carlos, Montes-Worboys, Ana, Planas-Cerezales, Lurdes, Buendia-Flores, Raquel, Molina-Molina, Maria, Vicens-Zygmunt, Vanesa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225674/ https://www.ncbi.nlm.nih.gov/pubmed/30409203 http://dx.doi.org/10.1186/s12931-018-0924-7

Ejemplares similares

Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2016)

Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts
por: Machahua, Carlos, et al.
Publicado: (2021)

Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis
por: Maldonado, Mariel, et al.
Publicado: (2018)

Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome
por: Bordas-Martínez, Jaume, et al.
Publicado: (2021)

Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction
por: Planas-Cerezales, Lurdes, et al.
Publicado: (2021)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Add-on therapy for pulmonary fibrosis, a forthcoming era with implications for practice: the BI 101550 and RELIEF trials
por: Planas-Cerezales, Lurdes, et al.
Publicado: (2023)

Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

Erratum to: Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

Predictors and changes of physical activity in idiopathic pulmonary fibrosis
por: Badenes-Bonet, Diana, et al.
Publicado: (2022)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Harnessing PM2.5 Exposure Data to Predict Progression of Fibrotic Interstitial Lung Diseases Based on Telomere Length
por: Shull, Jessica Germaine, et al.
Publicado: (2022)

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
por: Bordas-Martinez, Jaume, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis and the role of genetics in the era of precision medicine
por: Alonso-Gonzalez, Aitana, et al.
Publicado: (2023)

Mitochondrial Dysfunction in Lung Resident Mesenchymal Stem Cells from Idiopathic Pulmonary Fibrosis Patients
por: Mercader-Barceló, Josep, et al.
Publicado: (2023)

Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2020)

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey
por: Moor, Catharina C., et al.
Publicado: (2019)

Telomere Shortening Is behind the Harm of Immunosuppressive Therapy in Idiopathic Pulmonary Fibrosis
por: Molina-Molina, Maria
Publicado: (2019)

Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes
por: Arias-Salgado, Elena G., et al.
Publicado: (2019)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2019)

Increased Expression of CC16 in Patients with Idiopathic Pulmonary Fibrosis
por: Buendía-Roldán, Ivette, et al.
Publicado: (2016)

The JAK2 pathway is activated in idiopathic pulmonary fibrosis
por: Milara, Javier, et al.
Publicado: (2018)

Blood Biomarkers in Idiopathic Pulmonary Fibrosis
por: Guiot, Julien, et al.
Publicado: (2017)

The perplexing role of RAGE in pulmonary fibrosis: causality or casualty?
por: Perkins, Timothy N., et al.
Publicado: (2021)

Effects of Early Physical Therapy and Follow-Up in Acute Severe Coronavirus Disease 2019 Pneumonia: A Retrospective Observational Study
por: Bordas-Martínez, Jaume, et al.
Publicado: (2022)

Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis
por: Yamaguchi, Kakuhiro, et al.
Publicado: (2020)

Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1
por: Estany, Susanna, et al.
Publicado: (2014)

Macrophage-Derived Biomarkers of Idiopathic Pulmonary Fibrosis
por: Bargagli, E., et al.
Publicado: (2011)

Biomarkers of cellular senescence in idiopathic pulmonary fibrosis
por: Aversa, Zaira, et al.
Publicado: (2023)

Prognostic Value of Serum Biomarkers in Patients with Idiopathic Pulmonary Fibrosis in Relation to Disease Progression
por: Domvri, Kalliopi, et al.
Publicado: (2023)

Editorial: Translational research in severe COVID-19 and long-term symptoms post-COVID-19
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2023)

CD4+T cells in ageing-associated interstitial lung abnormalities show evidence of pro-inflammatory phenotypic and functional profile
por: Machahua, Carlos, et al.
Publicado: (2021)

Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry
por: Fernández-Fabrellas, Estrella, et al.
Publicado: (2019)

Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis
por: Kaarteenaho, Riitta, et al.
Publicado: (2015)

Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis
por: Sokai, Akihiko, et al.
Publicado: (2017)

Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis
por: Njock, Makon-Sébastien, et al.
Publicado: (2019)

PCSK6 and Survival in Idiopathic Pulmonary Fibrosis
por: Oldham, Justin M., et al.
Publicado: (2023)

Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis
por: Wu, Rui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3v59kgdlfjlc6f11tqbvhqatt8